SURGIFLO Hemostatic Matrix: payments to doctors
Payments that named SURGIFLO Hemostatic Matrix as the associated device or medical supply, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.5M
- Providers
- 5,454
- Transactions
- 7,124
- Average per transaction
- $207
The per-transaction average — $207 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,454 providers the average total is $271, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Johnson & Johnson | $886,117 | 60.1% |
| Medical Device Business Services, Inc. | $581,535 | 39.4% |
| Ethicon Endo-surgery Inc. | $5,440 | 0.4% |
| Johnson And Johnson International | $2,483 | 0.2% |